Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial (SPRINTR)

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: a Multicentre, Pragmatic Randomized Trial

As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical. Nicotinamide is a form of Vitamin B3 that has been shown to protect against skin cancer in the general population. However, it is unclear whether nicotinamide is effective among immune-suppressed transplant recipients. Investigators will conduct a clinical trial involving multiple transplant centres in Canada to evaluate whether oral nicotinamide (500 mg twice daily) is effective and safe for preventing skin cancer. Investigators will recruit 396 high-risk adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Patients will receive nicotinamide or sham tablets for up to 4 years. The results will inform efforts to improve the long-term health of transplant recipients.

Improved survival after solid organ transplantation has created the need to better prevent the long-term adverse effects of immunosuppressant drugs in transplant survivors - particularly cancer development. Keratinocyte carcinoma (non-melanoma skin cancer) is by far the most common form of post-transplant malignancy and has a more aggressive clinical course than in the general population. Preventive measures are thus critical to reduce the burden of skin cancer in the high-risk transplant population. Nicotinamide is a low-cost, commercially available, over-the-counter Vitamin B3 derivative that has been found to safely reduce the rate of keratinocyte carcinoma in immunocompetent patients with a history of skin cancer. It is unclear whether its efficacy and safety translate to the immunosuppressed transplant population. Given this uncertainty, Investigators plan to build on our internal pilot study (N=120) to conduct the SPRINTR (Skin cancer PRevention with Nicotinamide in Transplant Recipients) pivotal trial to address these specific aims: Primary question: Does oral nicotinamide (500 mg twice daily) reduce the rate of further keratinocyte carcinoma compared with placebo when used in addition to standard care for up to 208 weeks in high-risk solid organ transplant recipients? Secondary questions: What is the safety of nicotinamide when used in addition to standard care for up to 208 weeks in the transplant population? What is the effect of nicotinamide on quality of life related to skin cancer? Investigators will conduct a multicentre, pragmatic, parallel group, investigator- and patient-blinded, randomized trial with a superiority framework. This pivotal trial will evaluate the efficacy and safety of oral nicotinamide versus placebo to prevent further keratinocyte carcinoma in 396 high-risk solid organ transplant recipients. Data from our previous internal pilot study (N=120 participants) will be combined with data from the current pivotal trial (N=276 additional patients) in the final analysis.

Multicentre, parallel group, placebo-controlled, pragmatic randomized trial with 1:1 allocation and a superiority framework

Time to first biopsy-confirmed keratinocyte carcinoma (basal cell carcinoma or invasive cutaneous squamous cell carcinoma)

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)

As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)

As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)

As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)

As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest

Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest

Inclusion Criteria: Age ≥ 18 years old Kidney, liver, heart, or lung transplant at least two years ago History of at least one prior histologically-confirmed keratinocyte carcinoma or squamous cell carcinoma in situ Currently immunosuppressed with a calcineurin inhibitor-based regimen (cyclosporine or tacrolimus) Able to attend follow-up visits Exclusion Criteria: Use of nicotinamide or niacin (≥250 mg daily) within past 12 weeks Untreated localized skin cancer at baseline (patient can enrol after skin cancer treatment) Biopsy-confirmed acute rejection episode within the past 12 weeks Active liver disease (high AST >3 times or bilirubin >1.5 times) Severe kidney disease (estimated glomerular filtration rate <20 mL/min/1.73 m2) Solid organ or hematologic malignancy, invasive melanoma, Merkel cell carcinoma, or metastatic skin cancer within the past five years Pregnancy or lactation Need for ongoing carbamazepine or primidone Allergy to nicotinamide or any ingredient of the vitamin or placebo capsules

The trial protocol and statistical code will be shared upon request. Beyond 18 months after trial completion, the anonymized participant-level dataset will made available for sharing with external researchers upon approval of a reasonable study proposal describing the intended data usage.